RAPT
HealthcareRAPT Therapeutics, Inc.
$29.82
$-2.03 (-6.37%)
Jan 5, 2026
Price History (1Y)
Analysis
RAPT Therapeutics, Inc. is a biotechnology company in the healthcare sector with 60 employees. The company's market capitalization stands at $826.34 million. The financial health of RAPT Therapeutics reveals significant losses, with net income totaling -$105,637,000 and EBITDA reaching -$111,664,000 over the trailing twelve months. Free cash flow is also negative, coming in at -$46,387,500. The company maintains a substantial amount of cash on hand, holding $157.34 million in cash reserves while having relatively low debt of $2.60 million. Return on equity and return on assets are both significantly negative, indicating the company's current financial struggles. RAPT Therapeutics' valuation metrics include a price to book ratio of 3.31 and an EV/EBITDA of -6.52. The forward P/E ratio is -9.54, suggesting a complex or challenging valuation situation due to the reported losses.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $826.34M
- P/E Ratio
- N/A
- 52-Week High
- $42.39
- 52-Week Low
- $5.66
- Avg Volume
- 502.69K
- Beta
- 0.46
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 60